Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 623-629 , August 2009

Multipoint analysis of reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism

  • Nobuyoshi Fukumitsu

      Affiliations

    • Proton Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 29 853 7100; fax: +81 29 853 7102.
    • ,
  • Masahiko Suzuki

      Affiliations

    • Department of Neurology, The Jikei University School of Medicine, Tokyo 105-8461, Japan
    • ,
  • Takahiro Fukuda

      Affiliations

    • Department of Neuroscience, Research Center of Medical Science, The Jikei University School of Medicine, Tokyo 105-8461, Japan
    • ,
  • Yasushi Kiyono

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan

Received 11 March 2009 ,Revised 27 March 2009 ,Accepted 2 April 2009.

References 

  1. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22–31
  2. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med. 1993;34:1140–1146
  3. Linden D, Diehl RR, Berlit P. Sympathetic cardiovascular dysfunction in long-standing idiopathic Parkinson's disease. Clin Auton Res. 1997;7:311–314
  4. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997;38(Suppl 2):2–7
  5. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2003;2:669–676
  6. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-Metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:189–194
  7. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of [123]I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun. 1998;19:137–142
  8. Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med. 1999;40:371–375
  9. Suzuki M, Urashima M, Oka H, Hashimoto M, Taira K. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease. NeuroReport. 2007;18:1867–1870
  10. Spiegel J, Hellwig D, Farmakis G, Jost WH, Samnick S, Fassbender K, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord. 2007;22:1004–1008
  11. Mitsui J, Saito Y, Momose T, Shimizu J, Arai N, Shibahara J, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006;243:101–104
  12. Orimo S, Amino T, Yokochi M, Kojo T, Uchihara T, Takahashi A, et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord. 2005;20:1350–1353
  13. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, Wakabayashi K, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;73:776–777
  14. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol. 1991;208:273–286
  15. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 1993;61:1191–1206
  16. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–980
  17. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1983;80:4546–4550
  18. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 1987;405:26–38
  19. Sonsalla PK, Heikkila RE. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol. 1986;129:339–345
  20. Fuller RW, Hahn RA, Snoddy HD, Wikel JH. Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol. 1984;33:2957–2960
  21. Fuller RW, Hemrick-Luecke SK, Robertson DW. Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine. Biochem Pharmacol. 1988;37:3343–3347
  22. Wallace RA, Boldry R, Schmittgen T, Miller D, Uretsky N. Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. Life Sci. 1984;35:285–291
  23. Hemrick-Luecke SK, Mitch CH, Quimby SJ, Fuller RW. Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine, an analog of MPTP, on mouse heart norepinephrine and brain catecholamines. Neurochem Int. 1993;23:467–470
  24. Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med. 2000;41:71–77
  25. Takatsu H, Wada H, Maekawa N, Takemura M, Saito K, Fujiwara H. Significant reduction of 125I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease. Nucl Med Commun. 2002;23:161–166
  26. Fukumitsu N, Suzuki M, Fukuda T, Kiyono Y, Kajiyama S, Saji H. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism. Nucl Med Biol. 2006;33:37–42
  27. Amino T, Uchihara T, Tsunekawa H, Takahata K, Shimazu S, Mizusawa H, et al. Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. Neurosci Res. 2008;60:314–318
  28. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging. 2002;29:999–1005
  29. Kiyono Y, Iida Y, Kawashima H, Tamaki N, Nishimura H, Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med. 2001;28:894–899
  30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  31. Sundstrom E, Fredriksson A, Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 1990;528:181–188
  32. Ricaurte GA, Langston JW, Delanney LE, Irwin I, Peroutka SJ, Forno LS. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 1986;376:117–124
  33. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol. 1989;10:171–183
  34. Marien M, Briley M, Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol. 1993;236:487–489
  35. Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Taki K, et al. [123I]Meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med. 2003;42:127–128
  36. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005;15:29–34
  37. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO, Quyyumi AA, et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation. 1992;85:1775–1785
  38. Algeri S, Ambrosio S, Garofalo P, Gerli P. Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. Eur J Pharmacol. 1987;141:309–312

☆ This work was supported by a Grant-in-Aid for Scientific Research (C) (No. 17591243).

PII: S0969-8051(09)00086-9

doi: 10.1016/j.nucmedbio.2009.04.001

Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 623-629 , August 2009

Article Tools

* Image Usage & Resolution